Akanda (AKAN) Receivables - Accured (2024 - 2025)
Akanda's (AKAN) quarterly Receivables - Accured came in at $92638.0 in Q4 2025, up 1337.14% year-on-year from $6446.0 in Q4 2024, and up 1337.14% quarter-over-quarter from $6446.0 in Q4 2024.
Akanda (AKAN) Receivables - Accured (2024 - 2025) Analysis & Trends
Akanda's Receivables - Accured history runs 2 years deep, the most recent figure standing at $92638.0 for Q4 2025.
- On a quarterly basis, Receivables - Accured rose 1337.14% year-over-year to $92638.0 in Q4 2025; TTM through Dec 2025 was $92638.0, a 1337.14% increase from a year earlier, with the FY2025 full-year figure at $92638.0, up 1337.14% from the prior year.
- Receivables - Accured climbed to $92638.0 in Q4 2025 per AKAN's latest filing, from $6446.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $92638.0 in Q4 2025 and bottomed at $6446.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Akanda | 556,353.85 | 556,353.85 | - | 92,638.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 92,638.00 |
| Dec 31, 2025 | 92,638.00 |
| Dec 31, 2024 | 6,446.00 |
| Dec 31, 2024 | 6,446.00 |